Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus

Diabetes/metabolism research and reviews

Volumn 30, Issue 7, 2014, Pages 556-569

  Hirshberg, Boaz ^a   Parker, Artist ^a   Edelberg, Helen ^a   Donovan, Mark ^a   Iqbal, Nayyar ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

adverse events; dipeptidyl peptidase 4 inhibitor; hypoglycaemia; incretin; saxagliptin; type 2 diabetes mellitus

Indexed keywords

ADAMANTANE; DIPEPTIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; INCRETIN; SAXAGLIPTIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; DIABETES MELLITUS, TYPE 2; DOSE RESPONSE; FEMALE; HUMAN; MALE; META ANALYSIS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; TREATMENT OUTCOME; VERY ELDERLY;

ADAMANTANE; ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INCRETINS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 84919794258     PISSN: None     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2502     Document Type: Article

References (0)